Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Despite significant progress in expanding health insurance coverage since the Affordable Care Act (ACA) was enacted, millions of Americans still face critical gaps in access and affordability to health care.

Despite Record ACA Enrollment, Report Reveals Underinsured Americans are in Crisis

Evidence highlights the predictive value of the stress hyperglycemia ratio for mortality risk in patients with acute myocardial infarction, ischemic stroke, and acute heart failure.

Elevated Stress Hyperglycemia Ratio Linked to Higher All-Cause Mortality After Cardiovascular Events

 in 2023, where she produces written content covering multiple disease states.

She has a BA in journalism from Seton Hall University. You can connect with Brooke on 

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.

New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease 

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Redefining Menopause Management: Addressing Gaps, Embracing Innovations, and Enhancing Outcomes 

Safety Profiles of Neurokinin-Targeted Therapies for VMS

Video content above is prompted by the following:

What notable adverse events were observed in the OASIS trials with elinzanetant?

 How do these safety profiles of elinzanetant and fezolinetant compare with traditional treatments?

Videos

Panelists discuss how innovative neurokinin-targeted therapies for vasomotor symptoms can reshape menopause management and address unmet needs and improving patient outcomes while highlighting the importance of equity in treatment access.

Understanding the Burden of Menopausal Vasomotor Symptoms

Panelists discuss how underlying factors, including patient resistance to conventional treatments and the stigma surrounding menopause, contribute to the persistent undertreatment of vasomotor symptoms (VMS), which can severely impact women’s quality of life and increase their risk for long-term health issues such as cardiovascular disease and Alzheimer disease.

Barriers to VMS Treatment and Impact on Long-Term Health

Panelists discuss how to improve treatment rates for vasomotor symptoms (VMS) by identifying actionable steps, examining the influence of socioeconomic status on health care access, and proposing initiatives to ensure equitable care for all women experiencing menopause.

Improving Access and Equity in VMS Treatment

Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.

Integrating VMS Treatment Into Comprehensive Women’s Health Management

Panelists discuss the role of neurokinin in the pathophysiology of vasomotor symptoms (VMS) and examine the mechanisms of action of novel nonhormonal agents such as fezolinetant and elinzanetant, highlighting the advantages of targeting neurokinin pathways over traditional hormonal treatments and their potential to address related menopause issues such as mood disturbances and sleep disorders.

Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.

Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) compared with other treatments, as well as its impact on quality of life and the speed at which patients experienced symptom improvement.

Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

Panelists discuss the notable adverse events observed in the OASIS trials with elinzanetant and compare the safety profiles of elinzanetant and fezolinetant with those of traditional treatments for vasomotor symptoms (VMS).

Elinzanetant was evaluated in the OASIS 1, 2, and 3 trials, focusing on its efficacy in reducing the frequency and severity of vasomotor symptoms (VMS) in menopausal women. The trials demonstrated significant improvements in VMS, with rapid symptom relief compared to both hormonal and nonhormonal treatments. Elinzanetant also positively impacted the quality of life for women with severe VMS. Adverse events were noted, and the safety profile of elinzanetant was compared with fezolinetant and traditional treatments, highlighting its potential as a viable alternative.

Safety Profiles of Neurokinin-Targeted Therapies for VMS

EP: 1.Understanding the Burden of Menopausal Vasomotor Symptoms

EP: 2.Barriers to VMS Treatment and Impact on Long-Term Health

EP: 3.Improving Access and Equity in VMS Treatment

EP: 4.Integrating VMS Treatment Into Comprehensive Women’s Health Management

EP: 5.Advances in Menopause Treatment: A Focus on the Neurokinin Pathway

EP: 6.Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

EP: 7.Elinzanetant and the OASIS Trials: Quality of Life and Symptom Relief

EP: 8.Safety Profiles of Neurokinin-Targeted Therapies for VMS